Competitor Landscape: Rheumatoid Arthritis

Competitor Landscape: Rheumatoid Arthritis

Summary

Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Key Highlights

- If the results of the Phase II MANTA safety trial are required by the FDA prior to filing for regulatory approval of filgotinib for RA, this could delay US approval by 2 years
- Given that the Phase II NCT03241108 trial is limited to 90 patients in the EU, it is likely that NovImmune will need to initiate a second Phase II trial with a larger number of patients, including US patients, prior to proceeding with a Phase III program for NI-0101 in RA
- The Phase II trial assessing the immunogenicity and safety of Zostavax in RA patients using abatacept, if positive, is likely to boost physician opinion of abatacepts safety profile in RA, and reduce potential physician concerns that the use of abatacept may negatively impact the effectiveness of some immunizations, as suggested by its US FDA label.

Scope

- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Introduction to Sociable Pharmas Competitor Landscape
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor Direction of Travel
Pipeline Landscape
Pipeline Summary
Approved Product Development Landscape
Lifecycle Development
Appendix

Competitor Landscape: Inflammatory Bowel Disease (IBD)

Competitor Landscape: Inflammatory Bowel Disease (IBD)Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the IBD market, analysis of current & potential future product positioning, and forecast approval

USD 6400 View Report

Competitor Landscape: Lupus

Competitor Landscape: LupusSociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Lupus market, analysis of current & potential future product positioning, and forecast approval dates (by quarter)

USD 6400 View Report

Competitor Landscape: Inflammatory Bowel Disease (IBD)

Competitor Landscape: Inflammatory Bowel Disease (IBD)Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the IBD market, analysis of current & potential future product positioning, and forecast approval

USD 6400 View Report

Competitor Landscape: Lupus

Competitor Landscape: LupusSociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Lupus market, analysis of current & potential future product positioning, and forecast approval dates (by quarter)

USD 6400 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available